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Is there any association between chronic Hepatitis C virus
and celiac disease?
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Background: Celiac disease (CD) is an immune-mediated
disorder associated with some autoimmune liver diseases,
including primary biliary cirrhosis, autoimmune hepatitis
and primary sclerosing. In addition, there are contradictory
reports on association of chronic hepatitis C (HCV) and celiac
disease. The aim of this study was to determine the preva-
lence of untreated celiac disease and Hepatitis C Virus in
Iranian pregnant women and assess the outcome of preg-
nancy compared to non-celiac cases.
Methods: In this cross sectional study, 827 pregnant
women were recruited for this study during the period of
January 2007- February 2009. The mean age was 26.07
and SD 5.35 and mean pregnancy 5.4 months. Data were
obtained through questionnaires distributed during preg-
nancy. The questionnaire included questions about GI
symptoms and infections during pregnancy. They underwent
a total IgA test and antihuman IgA class antitissue transglu-
taminase (tTGA) antibodies for celiac disease and samples
also screened for anti- HCV antibodies by Third generation
enzyme linked immunosorbent assay.
Results: From 827 pregnant women 27 (3.26%) had a
positive serology for tTGA. Only two samples (0.24%) were
anti-HCV positive and one of them had positive tTG-IgA.
Eleven cases from 827 had IgA deﬁciency and none of them
were positive for IgG-tTG. Out of the 27 diagnosed women,
three had low birth weight babies and four had a history of
miscarriage.
Conclusion: Routine screening of HCV in CD patients is
not recommended, however, the presence of CD should be
considered in the setting of clinical deterioration during the
pregnancy.
doi:10.1016/j.ijid.2010.02.2006
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Prevailing HCV genotypes and subtypes among HIV
infected patients in Georgia
M. Karchava ∗, L. Sharvadze, L. Gatserelia, L. Dzigua, N.
Dvali, T. TsertsvadzeInfectious Diseases, AIDS and Clinical Immunology Research
Center, Tbilisi, Georgia
Background: Recent analysis of ART program data in
Georgia showed that end-stage liver disease is leading cause
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f death among HIV/HCV co infected patients on ART after
nitiation of ART program in 2005. Therefore, treatment of
epatitis C among HIV infected individuals is essential for
ustaining success of ART in Georgia and to improve sur-
ival rates of HIV infected patients. HCV treatment response
ate and sustained viral suppression after antiviral treat-
ent largely depends on the HCV genotypes along with the
nﬂuence of HIV co- infection itself. The objective of this ret-
ospective study was to study the prevailing genotypes and
ubtypes of HCV virus in a cohort of HIV infected patients in
rder to obtain the preliminary data.
Methods: We analyzed 1490 HIV infected patients co
nfected with HCV virus. Among them 59% were HCV coin-
ected. Measurement of HCV RNA viral load was done by
OBAS TaqMan HCV-2.0 Test and HCV genotyping by reverse
ybridization line probe assay using VERSANT HCV Genotype
it 2.0 respectively.
Results: Detectable HCV RNA was found among 680
atients (91.%). Less than 10 Iu/ml was found among among
7 (9%). This numbers indicate low rate of self clearance
f the virus among HIV persons. Greater HCV RNA levels
ere associated with a greater chance to be infected with
CV genotypes 1. Most prevalent genotypes were genotype 1
ccounting for (41.6%), followed by genotype 3 (34.7%) and
(17.6%), inter genotype recombinants were found among
.8%.
Conclusion: Study demonstrated high prevalence of HCV
nfection among HIV-infected patients and reveals 1 as
redominant genotype. The differences of prevailing HCV
enotypes among general population and HIV co infected
roup was probably attributed to the different methods
or sample selection used. Another option can be possi-
le inﬂuence of diverse transmission networks among HIV
nfected group. The high number of intergenotype recom-
inants might be results of continues parenteral exposure
o different HCV genotypes during drug injection parapher-
alia. Study highlights and strengthens the need for careful
ollow-up of HCV/HIV co infected patients, effective man-
gement and therapies against HCV in order to reduce liver
elated death rates in patients on ART.
oi:10.1016/j.ijid.2010.02.2007
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epatitis B Virus (HBV) mutations during long-term ther-
py in chronic hepatitis B patients
. Arrese1, M. Basaras2, S. Blanco3, P. Ruiz3, R. Cisterna4,∗
University of Basque Country, Vitoria-Gasteiz, Spain
University of Basque Country, Bilbao, Spain
Basurto Hospital, Bilbao, Spain
Basque Country / Basurto Hospital, Bilbao, Spain
Background: Long-term lamivudine (LAM), adefovir (ADV)
nd entecavir (ETV) treatment has been found to induce
he emergence of drug-resistant hepatitis B virus (HBV) in a
igniﬁcant number of patients with chronic hepatitis B infec-
ion. The aim of our study was to evaluate the LAM, ADV and
TV mutations detected in our patient group.
Methods: Fifteen patients diagnosed with chronic hepati-
is B were enrolled in this study. The patient group consisted
f those who had received two years of treatment with
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ucleos(t)ide analogues. Patients were evaluated based on
irologic and serologic response to therapy, and were clas-
iﬁed as patients with a detectable level of HBV DNA and
ndetectable HBV DNA (<1.08 log copies/ml). The muta-
ions associated with HBV drug resistance were investigated
n patients with detectable HBV DNA. Due to resistance, in
his group of patients treatment was change.
Results: In our study group, four patients devel-
ped LAM-associated mutations (rtL180M+rtM204V,
tL180M+rtM204V/I, and 2 present rtM204I), three patients
eveloped ADV-associated mutations (rtA181V+rtN236T;
tN236T and rtA181V), one patient developed ADV+LAM
ssociated mutations (rtL180M+rtA181V+rtN236T) and
ther patient developed ETV-associated mutations
rtL180M+rtT184A+rtS202G+rtM204V). Beside the primary
esistant mutations, various combinations of secondary
nd compensatory mutations conferring resistance to
ucleos(t)ide analogues were detected in 5 (33%) patients.
Conclusion: HBV treatment with nucleoside analogues
esults in the development of mutants strains, leading
o drug resistance. These data suggest an early develop-
ent of ETV resistance in patients with prior LAM and ADV
esistance. Therefore genotypic resistance is important in
onitoring HBV treatment. In conclusion, optimization of
herapy combining LAM and ADV may be a good choice for
atients with hepatitis B who have resistance mutations to
DV or LMV.
oi:10.1016/j.ijid.2010.02.2008
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Background: Over the last few years a new concept
as intoduced a possibility a SVR may indicate cure. VHC-
RN clearence at 6 months after therapy discontinuation
VR (sustained virologic response) is generally assumed as
robable cure. The medical literature shows a signiﬁcative
eduction in the rate of progression to cirrosis and Hep-
tocarcinoma development in patients who achieved SVR
ompared to non responders and relapsers.
Methods: We retrospectively analysed a group of VHC
atients that fulﬁlled histologic criteria for antiviral treat-
ent from 1998 to 2009. We performed VHC ARN PCR
eterminations at baseline, during treatment, in the last
eek of antiviral treatment, every 6 months’ until the 2◦
ear after therapy discontinuation. and once a year further
n. We deﬁned ETR as negative or undetectable ARN VHC
CR in the last week of antiviral treatment.
Results: In our study 38 patients achieved ETR (nega-
ive VHC PCR during the ﬁnal week of IFN treatment). Only
e
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patients that achieved ETR showed early relapse in the
ext six months after stopping therapy (so they not achieved
VR). The rest of the patients are not detectable up to the
ast control., in the long term follow up.
Conclusion: In this small group of patients we didn‘t ﬁnd
elapses after 6 months following discontinuation of therapy,
ith a mean follow up of nearly 10 years The period of higest
isk of relapses was the next 12 months after the end of
reatment. The rate of relapses after 24 months of the end
f treatment was very low, as estimated in different studies
etween 1 and 2%.
oi:10.1016/j.ijid.2010.02.2009
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ent from south and southeast region of Brazil
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Background: The objectives were to estimate the preva-
ence of hepatitis A among children and adolescents from
outh and southeast region of Brazil and to identify
ndividual-, household- and area-levels factors associated
ith hepatitis A infection.
Methods: This population-based survey was conducted
n 2007—2008 and covered individuals aged between 5 and
9 years. A stratiﬁed multistage cluster sampling technique
ith probability proportional to size was used to select
.054 individuals aged between 5 and 19 years living in
he State capitals of 7 states in the study regions. The
ample was stratiﬁed according to age (5—9 and 10- to
9-years-old) and capital within each region. Individual-
nd household-level data were collected by interview at
he home of the individual. Variables related to the area
ere retrieved from census tract data. The outcome was
otal antibodies to hepatitis A virus detected using com-
ercial EIA. The associations between HAV infection and
ndependent variables were assessed using the odds ratio
nd corrected for the random design effect and sampling
eight. Multilevel analysis was performed by GLLAMM using
tata 9.2.
Results: The prevalence of hepatitis A infection in the
—9 and 10—19 age-group was 20,6 and 37,7%, respec-
ively for the Southeast and, 18,9 and 34,5%, respectively
or the South. A trend for the prevalence of HAV infec-
ion to increase according to age was detected in all sites.
ultilevel modeling showed that variables relating to differ-
nt levels of education were associated with HAV infection
n all sites. The multilevel model showed that individual,
ousehold- and area-level variables are independently asso-
iated with HAV infection. Age is an important predictor of
